The market growth can be attributed to several factors such as the increasing prevalence of neuroblastoma in children, improvements in the healthcare infrastructure, and rising R&D activities are anticipated to further contribute to this substantial market growth between 2019 and 2030. However, the high cost of this therapy is likely to restrain the growth of the market to a certain extent. Market Industry Reports (MIR) has published a new report titled “Pediatric Neuroblastoma Treatment Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019–2030.” According to the report, the Global Pediatric Neuroblastoma Treatment Market is estimated to account for over US$ 676.0 million by 2019. The market is anticipated to grow at a CAGR of ~8.6% from 2019 to 2030.
To obtain better insights regarding the market scenario, prominent players are increasingly focusing on collaborative initiatives with several institutes, research centres, and companies. For instance, In January 2020, EUSA Pharma and BeiGene, Ltd. announced that they have entered into an exclusive development and commercialization agreement for the orphan biologic products SYLVANT® (siltuximab) and QARZIBA® (dinutuximab beta) in Greater China. According to the American Society of Clinical Oncology (ASCO), in the U.S., neuroblastoma is the 3rd most common cancer found in children, accounting for more than 6% of childhood cancer and nearly 800 new cases of neuroblastoma are reported in the U.S. each year. Therefore, the rising incidences of pediatric neuroblastoma can be a major factor contributing to the growth of the market.
Major Key Players of the Pediatric Neuroblastoma Treatment Market are:
United Therapeutics Corporation, APEIRON Biologics AG., EUSA Pharma, CELLECTAR BIOSCIENCES, INC., Y-mAbs Therapeutics, Pfizer Inc., MacroGenics, Inc., Baxter, Bristol-Myers Squibb Company and Teva Pharmaceutical Industries Ltd. among others.
United Therapeutics Corporation, APEIRON Biologics AG., EUSA Pharma, CELLECTAR BIOSCIENCES, INC., Y-mAbs Therapeutics, Pfizer Inc., MacroGenics, Inc., Baxter, Bristol-Myers Squibb Company and Teva Pharmaceutical Industries Ltd. among others.
No comments:
Post a Comment